Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Rom, Italy Clinical Trials

A listing of Rom, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (649) clinical trials

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH)

The purpose of the study is to investigate whether corifollitropin alfa (MK-8962), administered in combination with human chorionic gonadotropin (hCG), increases the testicular volume in adolescent males aged 14 to <18. In addition, the study will evaluate participants for the development of corifollitropin alfa antibodies over the course of 64 ...

Phase

0.0 miles

Learn More »

European VOD Registry

Defitelio has been granted a Marketing Authorisation in Europe under exceptional circumstances. Defitelio is indicated for the treatment of severe hepatic Veno-Occlusive Disease (sVOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 ...

Phase N/A

0.0 miles

Learn More »

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_

The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

0.0 miles

Learn More »

Evaluation of Ablation Index and VISITAG (ABI-173)

The purpose of this study is to assess the safety, acute and long term effectiveness, during standard RF ablation procedures while using Ablation Index and VISITAG software in combination with a Thermocool SmartTouch (ST) or SmartTouch Surroundflow (STSF) catheter. Furthermore, the role of Ablation Index and VISITAG workflow in creating ...

Phase

0.0 miles

Learn More »

Study of ARQ 092 in Patients With Overgrowth Diseases and/or Vascular Anomalies

This is an open label, Phase 1/2 study of ARQ 092 administered orally. The primary objective of this study is to assess the safety of ARQ 092 in subjects (at least 2 years of age) with overgrowth diseases and/or vascular anomalies with documented genetic alterations of the PI3K/AKT pathway. The ...

Phase

0.0 miles

Learn More »

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation: patients who initiated maintenance treatment with aripiprazole once-monthly and patients who initiated maintenance treatment with any daily oral atypical antipsychotic. The date of maintenance treatment initiation will ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with DD-CKD

Phase

0.0 miles

Learn More »

A Study Evaluating the Efficacy and Safety of the LentiGlobin BB305 Drug Product in Subjects With Transfusion-Dependent -Thalassemia Who do Not Have a 0/ 0 Genotype

This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 23 subjects 50 years of age with transfusion-dependent -thalassemia (TDT), also known as -thalassemia major, who do not have a 0 mutation at both alleles of the hemoglobin (HBB) gene. The study will evaluate the efficacy and safety of ...

Phase

0.0 miles

Learn More »

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs Treatment Choice (TC). Approximately 408 subjects will be randomly assigned 2:1 to either guadecitabine or TC. Guadecitabine: approximately 272 subjects. TC: approximately 136 subjects. Before randomization, the investigator will assign each subject to one of the following TC options Low dose cytarabine ...

Phase

0.0 miles

Learn More »

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

The primary object is to estimate the Objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with International Metastatic RCC Database Consortium (IMDC) intermediate and high risk, advanced Renal ...

Phase

0.0 miles

Learn More »